Yonhap Infomax NewsNov 10
Yuhan Corp. and Johnson & Johnson's Janssen Korea have agreed to jointly promote the Leclaza–Rybrevant combination therapy for first-line treatment of EGFR-mutant non-small cell lung cancer in South Korea, leveraging strong Phase 3 trial results to expand market access and awareness among healthcare professionals.
#YonhapInfomax #YuhanCorp #JohnsonAndJohnson #Leclaza #Rybrevant #NonSmallCellLungCancer #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90019
Yuhan Corp. and Johnson & Johnson Launch Joint Domestic Promotion for 'Leclaza–Rybrevant' Combination Therapy

Yuhan Corp. and Johnson & Johnson's Janssen Korea have agreed to jointly promote the Leclaza–Rybrevant combination therapy for first-line treatment of EGFR-mutant non-small cell lung cancer in South Korea, leveraging strong Phase 3 trial results to expand market access and awareness among healthcare professionals.

Yonhap Infomax